Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus
systemic lupus erythematosus (SLE) is the most common autoimmune disease in women of childbearing age. Promoting physical activity is a major national priority for the general population, including patients with chronic diseases.
- Trial name
- NCT05392790
- Testing
- Progressive resisted exercise training, Calcium and Vit D, Aerobic exercises
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Cairo University
Inflammation, Systemic Lupus Erythematosus
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate the safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE) concomitantly…
- Trial name
- NCT01689025
- Testing
- NNC0114-0006
- Where
- 5 sites in United States, Hungary and 2 more
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Lupus Erythematosus, Systemic, Adverse Effects
Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
The purpose of this study is to investigate the relationship between the side effects of cyclophosphamide in the treatment of systemic lupus erythematosus (SLE) in Han Chinese and the genetic polymorphisms of drug metabolizing…
- Trial name
- NCT01060410
- Testing
- Polymorphism Analysis, Cyclophosphamide, Pharmacokinetic analysis
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sun Yat-sen University
Lupus Arthritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams [mg] and 1 mg) in participants with active lupus arthritis.
- Trial name
- NCT01085084
- Testing
- Laquinimod
- Where
- 22 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
System; Lupus Erythematosus
FLARE Lupus Research Study Systemic Lupus Erythematosus
The first phase of this pilot study will assess changes in quality of life at the end of a 16-week Mymee program in patients with moderate to severe SLE.
- Trial name
- FLARE (NCT03426384)
- Testing
- Mymee Program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mymee Inc.
Systemic Lupus Erythematosus, Systemic Sclerosis
Neutrophil Extracellular Traps in Systemic Sclerosis
Systemic sclerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Trial name
- NET-SSC (NCT03374618)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Systemic Lupus Erythematosus
CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
The purpose of the study is to explore the safety and efficacy of cluster of differentiation 19 (CD19)/B cell maturation antigen (BCMA) CAR-T cell therapy in refractory/moderate-to-severe systemic lupus erythematosus(SLE).
- Trial name
- NCT06349343
- Testing
- CD19/BCMA CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lupus Erythematosus, Systemic
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus…
- Trial name
- NCT02070978
- Testing
- Atacicept 75 mg, Atacicept 150 mg
- Where
- 84 sites in United States, Argentina and 15 more
- Volunteers
- 253 people
- Sponsor
- EMD Serono
Lupus Erythematosus, Systemic
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage.
- Trial name
- DYSALARM-322 (NCT05193591)
- Testing
- Autoantibodies evaluation in lupus
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erythematosus
Catalytic Antibodies and Lupus in Martinique
The Martinique island (French West-Indies) is an area of high prevalence and incidence for Systemic Lupus Erythematosus (SLE), respectively 64,2/ 100000 and 4,7/ 100000.
- Trial name
- LUMAB2 (NCT01157468)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital Center of Martinique
Systemic Lupus Erythematosus
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
- Trial name
- Tulip SC (NCT04877691)
- Testing
- Medi-546
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Autoimmune Diseases
Deciphering the Genetic Architecture of Autoimmune Diseases
Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors.
- Trial name
- NCT06948110
- Where
- 2 sites in United States, Peru
- Volunteers
- 300 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Systemic Lupus Erythematosus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms.
- Trial name
- SHIELD (NCT05799378)
- Testing
- Hydroxychloroquine
- Where
- 12 sites in United States
- Volunteers
- 330 people
- Sponsor
- NYU Langone Health
Lupus Nephritis
Identifying New Therapeutic Targets for Lupus Treatment
Lupus is an autoimmune disease affecting mainly young women (9/1). Lupus nephritis (LN) occurs in 30% of the cases of lupus and is associated with end stage renal disease (ESRD) in 17 to 25% of cases after 10 years.
- Trial name
- ELUDIAL (NCT03921398)
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vasculitis, Systemic Lupus Erythematosus
Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit
Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, may affect multiple organ systems.
- Conditions
- Vasculitis, Systemic Lupus Erythematosus, Myositis
- Trial name
- NCT04022655
- Testing
- ICU Care
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Rheumatoid Arthritis, Psoriatic Arthritis
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- NCT04335747
- Testing
- COVID-19 infection
- Where
- Denmark
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Salome Kristensen
Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
- Trial name
- CAR-AID (NCT06249438)
- Testing
- CD20/BCMA-directed CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Sjogren Disease, Systemic Lupus Erythematosus
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
The purpose of this pharmacokinetic (PK) study is to describe the PK profile of ianalumab following s.c. administration in Chinese participants with systemic lupus erythematosus (SLE) and/or Sjögren's disease (SjD).
- Trial name
- NCT06411639
- Testing
- ianalumab
- Sponsor
- Novartis Pharmaceuticals
Vaccine Reaction, Zoster
Reduced Vaccine Response to HZ/su in SLE
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without…
- Conditions
- Vaccine Reaction, Zoster, Systemic Lupus Erythematosus
- Trial name
- NCT07636044
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Systemic Lupus Erythematosus (SLE), Refractory
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the…
- Trial name
- NCT06892145
- Testing
- MC-1-50
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.